Return to program book search
Uses and Toxicities of Oncologic Drugs in Dermatology
Saturday, March 02
3:30 PM - 5:30 PM
Jennifer N. Choi, MD, FAAD
- Sarah T. Arron, MD, PhD, FAAD
- Jaehyuk Choi, MD, PhD
- Mario E. Lacouture, MD, FAAD
- Jennifer Y. Lin, MD, FAAD
Following this course, the attendee should be able to:
- Examine the use of hedgehog pathway inhibitors, namely vismodegib, in treatment of basal cell carcinoma.
- Discuss the use, mechanism of action, and toxicities of vemurafenib and immunotherapies for melanoma.
- Discuss the use of systemic oncologic therapies for cutaneous diseases, such as EGFR inhibitors for cutaneous squamous cell carcinoma and imatinib for DFSP.
Novel targeted and biological therapies have become increasingly available in the treatment of cancer and other conditions. This is true also in the dermatologist's world. In this session, we will discuss recent advances in dermatologic therapies, including vismodegib for basal cell carcinoma, vemurafenib for melanoma, immunotherapies for melanoma, and the exploratory use of targeted agents, such as EGFR inhibitors for squamous cell carcinoma and imatinib for dermatofibrosarcoma protuberans and systemic mastocytosis. This session is directed to all general dermatologists, particularly those interested in the use of targeted and biological therapies.
|Saturday, March 02|
|3:30 PM||Introduction to Oncologic Drugs in Dermatology / Dr. Choi|
|3:35 PM||Hedgehog Pathway Inhibitors for Basal Cell Carcinoma / Dr. Arron|
|3:55 PM||Use and Toxicities of Vemurafenib in the Treatment of Melanoma / Dr. Lin|
|4:15 PM||Immunotherapies of Skin Cancer / Dr. Choi|
|4:35 PM||Use of Oncologic Drugs for Skin Disease / Dr. Lacouture|
|4:55 PM||Non-Surgical Modalities in Melanoma Treatment / Dr. Choi|
|5:15 PM||Question & Answer Session / All faculty|